Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031473 · ClinicalTrials.gov registry record · Phase 3
Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT00031473 is a Phase 3 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 90 participants.
The verdict
NCT00031473, a Phase 3 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and effectiveness of ribavirin, administered as an aerosol, in preventing progression of upper respiratory tract RSV infection to RSV pneumonia in bone marrow and peripheral blood transplant recipients.
Interventions
- DRUG Virazole (Ribavirin) Inhalation Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 1997-11 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00031473
The ClinicalTrials.gov registry entry for NCT00031473 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Virazole (Ribavirin) Inhalation Solution is the first listed.
NCT00031473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00031473 about?
NCT00031473 is a clinical study titled "Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients". The purpose of this study is to test the safety and effectiveness of ribavirin, administered as an aerosol, in preventing progression of upper respiratory tract RSV infection to RSV pneumonia in bone marrow and peripheral blood transplant recipients.
What is the current status of trial NCT00031473?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 1997-11. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00031473?
The interventions under investigation include: Virazole (Ribavirin) Inhalation Solution (DRUG).
Who is sponsoring clinical trial NCT00031473?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.